



Information and Privacy  
Commissioner of Ontario

Commissaire à l'information et à la  
protection de la vie privée de de l'Ontario

**VIA ELECTRONIC AND REGULAR MAIL**

October 31, 2017

Dr. Allan Seidenfeld  
President and CEO  
INSCYTE Corporation  
c/o AIM Inc.  
2 Berkeley Street, Suite 403  
Toronto, ON M5A 2W3

Dear Dr. Seidenfeld:

**RE: Review of the Report on the Practices and Procedures of the INSCYTE Corporation  
in respect of CytoBase**

Pursuant to subsection 13(2) of Regulation 329/04 under the *Personal Health Information Protection Act, 2004* ("the *Act*"), the Office of the Information and Privacy Commissioner of Ontario (IPC) is responsible for reviewing the practices and procedures implemented by an organization that has been designated as a prescribed person for the purposes of subsection 39(1)(c) of the *Act*, to protect the privacy of individuals whose personal health information it receives, and to protect the confidentiality of that information.

Given the practices and procedures of the INSCYTE Corporation (INSCYTE), a prescribed person within the meaning of the *Act*, were last approved on October 31, 2014, the IPC was again required to review these practices and procedures and advise whether they continue to meet the requirements of the *Act* on or before October 31, 2017.

In accordance with the process set out in the *Manual for the Review and Approval of Prescribed Persons and Prescribed Entities* ("the *Manual*"), INSCYTE, as a prescribed person seeking the continued approval of its practices and procedures, submitted a detailed written report and sworn affidavit to the IPC. These documents were to conform to the requirements set out in the *Manual*.

The IPC has now completed its review of your report and affidavit. Based on this review, I am satisfied that INSCYTE continues to have in place practices and procedures that sufficiently protect the privacy of individuals whose personal health information it receives, that sufficiently maintain the confidentiality of that information and that continue to meet the requirements of the *Act*.

Accordingly, effective October 31, 2017, I am pleased to advise that the practices and procedures of INSCYTE in respect of CytoBase continue to be approved for a further three-year period.

.../2



2 Bloor Street East  
Suite 1400  
Toronto, Ontario  
Canada M4W 1A8

2, rue Bloor Est  
Bureau 1400  
Toronto (Ontario)  
Canada M4W 1A8

Tel: (416) 326-3333  
1 (800) 387-0073  
Fax/Télé: (416) 325-9195  
TTY: (416) 325-7539  
Web: www.ipc.on.ca

I would like to extend my gratitude to you and your staff for your cooperation during the course of the review, including your diligence and timeliness in submitting the requested documentation, in responding to requests by my office for further information, and in making the amendments requested.

Sincerely,

Original signed by:

Brian Beamish  
Commissioner

cc: Jack Golabek, Privacy Officer